Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.37 |
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | METAP2 | P50579 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857659 | 1.00 | SLC6A4 (0.37) | SLC6A4HTR2CSLC6A2SLC6A3EPHX1 | |
| SCHEMBL4970893 | 1.00 | SLC6A4 (0.37) | SLC6A4HTR2CSLC6A2SLC6A3EPHX1 | |
| SCHEMBL1863892 | 0.99 | SLC6A4 (0.35) | SLC6A4HTR2CSLC6A2SLC6A3EPHX1 | |
| SCHEMBL8233820 | 0.81 | HTR2C (0.36) | SLC6A4HTR2CEPHX1 | |
| SCHEMBL3603986 | 0.80 | SLC6A2 (0.38) | SLC6A4SLC6A2SLC6A3EPHX1METAP2 | |
| SCHEMBL3595027 | 0.80 | SLC6A2 (0.38) | SLC6A4SLC6A2SLC6A3EPHX1METAP2 | |
| SCHEMBL1870673 | 0.78 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3EPHX1METAP2 | |
| SCHEMBL1863285 | 0.77 | SLC6A2 (0.34) | SLC6A4SLC6A2SLC6A3METAP2 | |
| SCHEMBL1859646 | 0.77 | SLC6A2 (0.34) | SLC6A4SLC6A2SLC6A3METAP2 | |
| SCHEMBL3770843 | 0.77 | HTR2C (0.37) | SLC6A4HTR2CEPHX1GAAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | SLC6A4 529/4885HTR2C 3907/4885SLC6A2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.